Friday, November 20, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > FDA Authorizes Novavax’s COVID Vaccine as Booster for Adults

FDA Authorizes Novavax’s COVID Vaccine as Booster for Adults

in News
FDA Authorizes Novavax’s COVID Vaccine as Booster for Adults
Share on LinkedinShare on WhatsApp

The Food and Drug Administration on Wednesday authorized Novavax COVID-19 vaccine as a booster for U.S. adults, including people unable to get updated Omicron boosters.

The authorization of Novavax’s booster could significantly increase its role in U.S. vaccination efforts. The Maryland based biotech’s vaccine was only authorized as a two-dose primary series, limiting its market for those already immunized with Pfizer or Moderna.

The FDA said adults ages 18 and older can receive Novavax as their third dose six months after completion of the primary series of any U.S. authorized Covid vaccine.

“According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults,” Novavax CEO Stanley Erck said in a statement Wednesday.

The FDA’s authorization of Novavax’s boosters comes as millions have already received Pfizer’s and Moderna’s new shots that target the omicron BA.5 subvariant and the original strain.

Despite Novavax’s booster being developed against the original strain, the company believes its protein technology is effective against different variants of the virus.

According to the CDC only 35,300 people have received Novavax’s shots as a primary series in the U.S.

U.S. health officials believe Pfizer and Moderna’s updated boosters will provide stronger protection than the first generation of vaccines because they target omicron BA.5, which is causing most infections right now.

Tags: COVID vaccineFDANovavax

Related Posts

Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment
News

Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Bending Spoons acquires Mailchimp in $3.68 billion deal
News

Bending Spoons acquires Mailchimp in $3.68 billion deal

PayPal appoints HP’s Enrique Lores as CEO
News

PayPal names Claire Bramley as new CFO

Google selects Bezos’ Blue Origin for AI space project
News

Google selects Bezos’ Blue Origin for AI space project

Anthropic sets $1 trillion IPO valuation target
News

Anthropic raises more than $81 billion in record IPO

Walmart beats predictions in latest quarter
News

Walmart raises outlook, anticipating a busy holiday season

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia shares rally following earnings beat

Target aims for non-alcoholic cocktail market ahead of the holiday season
News

Target reports its strongest sales growth in five years

Huang joins top CEOs on Trump’s China trip
News

Trump arrives in China for historic Xi, Putin meeting

The IMF-World Bank meetings commence in Washington
News

IMF chief gives stark warning on global economy 

No Result
View All Result

Recent Posts

  • Why are we so obsessed with the ’90s?
  • U.S. Loses Measles-Free Status After 26 Years
  • Plane clapping – joyful or deeply cringe?
  • The 4 themes shaping new manufacturing
  • Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.